S.anofi has lowered the US list price of two insulins, making it the third major maker of diabetes drugs to recently cut prices.
French drug maker Sanofi is slashing the U.S. list price of its most-prescribed insulin, Lantus, by 78%. statement Thursday. The company also cuts Apidra’s list price by 70% from his.
Olivier Bosillo, Head of General Medicines, US, said: “Our decision to lower the list price of our lead insulin must be combined with broader system-wide changes to really drive savings for patients at the pharmacy counter.”
read more: Insulin isn’t the only high cost for diabetics
The company also limits Lantus out-of-pocket costs to $35. The move, which will take effect in 2024, mirrors the steps taken by his rivals Eli Lilly & Co and Novo Nordisk A/S.
These price cuts by the three major insulin players have come under increasing pressure from lawmakers and advocates who have raised concerns about affordability for patients. The amount that manufacturers have to pay Medicaid in rebates will change soon, so we may see some financial benefits next year as a result of price cuts.
Novo announced on Tuesday that it is slashing the list price of the NovoLog and NovoLog Mix 70/30 by 75%. The company also has price cuts on Novolin and Levemir, as well as some unbranded insulin. Lilly, the first company to announce price changes earlier this month, is slashing Humalog and Humulin prices by 70%, capping out-of-pocket costs at $35.
Other must-read articles from TIME
